Pfizer Inc. (PFE) Shares Sold by Royal London Asset Management Ltd.
Royal London Asset Management Ltd. reduced its stake in Pfizer Inc. (NYSE:PFE) by 95.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,063,634 shares of the biopharmaceutical company’s stock after selling 41,414,391 shares during the period. Pfizer comprises approximately 1.2% of Royal London Asset Management Ltd.’s portfolio, making the stock its 15th largest position. Royal London Asset Management Ltd.’s holdings in Pfizer were worth $72,650,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Stelac Advisory Services LLC purchased a new position in shares of Pfizer during the second quarter worth approximately $110,000. Catamount Wealth Management boosted its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares in the last quarter. Commonwealth Financial Services LLC boosted its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares in the last quarter. Finally, Jag Capital Management LLC purchased a new position in shares of Pfizer during the second quarter worth approximately $202,000. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE:PFE) traded down 0.59% on Friday, hitting $33.94. The stock had a trading volume of 25,615,509 shares. The stock’s 50-day moving average is $35.23 and its 200 day moving average is $33.72. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The firm has a market capitalization of $205.87 billion, a price-to-earnings ratio of 30.09 and a beta of 0.87.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 1st. Shareholders of record on Friday, August 5th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Wednesday, August 3rd. This represents a $1.20 annualized dividend and a yield of 3.54%. Pfizer’s payout ratio is currently 95.24%.
PFE has been the topic of a number of recent research reports. Piper Jaffray Cos. set a $54.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, August 22nd. Jefferies Group dropped their price objective on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a report on Monday, August 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a report on Tuesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Pfizer currently has an average rating of “Buy” and a consensus target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.